| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| USRE46417 | ASTRAZENECA | Quinuclidine derivatives and their use as muscarinic M3 receptor ligands |
Feb, 2025
(1 year, 4 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6681768 | ASTRAZENECA | Powder formulation disintegrating system and method for dry powder inhalers |
Aug, 2022
(1 year, 1 month ago) | |
| US8051851 | ASTRAZENECA | Inhaler for the administration of powdered pharmaceuticals, and a powder cartridge system for use with this inhaler |
Apr, 2027
(3 years from now) | |
| US10085974 | ASTRAZENECA | Dosage and formulation |
Mar, 2029
(5 years from now) | |
| US11000517 | ASTRAZENECA | Dosage and formulation |
Mar, 2029
(5 years from now) | |
Duaklir Pressair is owned by Astrazeneca.
Duaklir Pressair contains Aclidinium Bromide; Formoterol Fumarate.
Duaklir Pressair has a total of 5 drug patents out of which 1 drug patent has expired.
Expired drug patents of Duaklir Pressair are:
- US6681768
Duaklir Pressair was authorised for market use on 29 March, 2019.
Duaklir Pressair is available in powder, metered;inhalation dosage forms.
Duaklir Pressair can be used as maintenance treatment of chronic obstructive pulmonary disease (copd).
The generics of Duaklir Pressair are possible to be released after 13 March, 2029.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Combination (NC) | Mar 29, 2022 |
Drugs and Companies using ACLIDINIUM BROMIDE; FORMOTEROL FUMARATE ingredient
Market Authorisation Date: 29 March, 2019
Treatment: Maintenance treatment of chronic obstructive pulmonary disease (copd)
Dosage: POWDER, METERED;INHALATION
DUAKLIR PRESSAIR family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic